Company Overview
Snapshot
Founded in January 2016, NTB Pharma operates with 1–10 employees. The company is in the Pre-Funding stage, focusing on developing novel targets for immuno-oncology and cancer immunotherapy.
Business overview
NTB Pharma is a Health Tech & Life Sciences company focused on developing novel targets for immuno-oncology and cancer immunotherapy. The company's core technology utilizes SLAM family receptors, hypothesizing that SLAMF6, a potent agonistic receptor on immune cells, can be a candidate for anti-melanoma immunotherapy. This approach aims for a dual action on lymphocytes and myeloid-derived suppressor cells, enhancing T-cell function and reversing the tumor environment's deleterious effects. NTB Pharma operates within the Pharmaceuticals sector, targeting the healthcare and life sciences industries.
Log in to access full profile ›Company Intelligence Q&A
- What is NTB Pharma's primary focus?
- NTB Pharma is focused on developing novel targets for immuno-oncology and cancer immunotherapy, specifically utilizing SLAM family receptors.
- When was NTB Pharma founded?
- NTB Pharma was founded in January 2016.
- What is the company's current employee count?
- NTB Pharma currently has 1–10 employees.
- What technology is NTB Pharma developing?
- NTB Pharma is developing technology based on SLAMF6, a highly potent agonistic receptor on immune cells, for anti-melanoma immunotherapy.
- What is the strategic advantage of NTB Pharma's approach?
- NTB Pharma's approach with SLAMF6 aims for a dual action on lymphocytes and myeloid-derived suppressor cells, which could augment T-cell function and reverse the negative effects of the tumor environment.